Matthias Riemenschneider
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matthias Riemenschneider has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
A. Kurz
Department of Psychiatry and Psychotherapy, Technische Universität München (TU-München), München, Germany
7 shared publications- Hans Förstl
Institut für Geschichte und Ethik der Medizin, TU München, München, Deutschland
7 shared publications A Kurz
Department of Psychiatry and Psychotherapy, Technische Universität München, Germany
4 shared publicationsS. Wagenpfeil
4 shared publications- Simon M. Laws
School of Diagnostic and Therapeutic Sciences, Curtin University, Kent Street, Bentley, WA, 6102, Australia
4 shared publications - Eugeen Vanmechelen
ADx NeuroSciences NV, Ghent, Belgium
3 shared publications
Latest Publications
- 31 August 2008
- Published by Elsevier in Neurobiology of Aging
- Vol. 29 (8) , 1276-1278
Genetic analysis of MAPT haplotype diversity in frontotemporal dementia
- 31 August 2008
- Published by Elsevier in Neurobiology of Aging
- Vol. 29 (8) , 1276-1278
Genetic analysis of MAPT haplotype diversity in frontotemporal dementia
- 30 November 2007
- Published by Elsevier in Neurobiology of Aging
- Vol. 28 (11) , 1789-1790
No association of chromatin-modifying protein 2B with sporadic frontotemporal dementia
- 30 November 2007
- Published by Elsevier in Neurobiology of Aging
- Vol. 28 (11) , 1789-1790
No association of chromatin-modifying protein 2B with sporadic frontotemporal dementia
- 30 June 2007
- Published by Elsevier in Neurobiology of Aging
- Vol. 28 (6) , 883-884
No association of Vacuolar protein sorting 26 polymorphisms with Alzheimer's disease
- 30 June 2007
- Published by Elsevier in Neurobiology of Aging
- Vol. 28 (6) , 883-884
No association of Vacuolar protein sorting 26 polymorphisms with Alzheimer's disease
- 31 May 2007
- Published by Elsevier in Neurobiology of Aging
- Vol. 28 (5) , 727-734
Weak independent association signals between IDE polymorphisms, Alzheimer's disease and cognitive measures
- 31 May 2007
- Published by Elsevier in Neurobiology of Aging
- Vol. 28 (5) , 727-734
Weak independent association signals between IDE polymorphisms, Alzheimer's disease and cognitive measures
- 16 June 2006
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 15 (16) , 2446-2456
A functional polymorphism within plasminogen activator urokinase (PLAU) is associated with Alzheimer's disease
A number of susceptibility loci for Alzheimer's disease (AD) have been identified including a region on Chromosome 10q21–q22. Within this region the plasminogen activator urokinase gene (PLAU) was considered as a reasonable candidate from its functional implication in plasmin generation, a serine protease capable of degrading beta-Amyloid (Aβ) protein. We screened 56 single nucleotide polymorphisms (SNPs) around PLAU using 1751 individuals from four independent case–control samples (Munich, N=679; Bonn N=282; Brescia (Italy) N=219; Perth (Australia) N=557 and one discordant sib-pair sample (Munich N=622). In brain tissue samples of neuropathologically confirmed cases with AD (N=33) we analyzed plaque counts according to the risk allele. We identified that one functional exonic SNP (rs2227564) is associated with development of AD using the four independent case–control samples (Munich, P=0.02; Bonn, P=0.005; Brescia (Italy), P=0.001; Perth (Australia), P=0.03) and the discordant sib-pair sample (P=0.001). In brain tissue, from neuropathologically confirmed cases with AD, we identified significantly higher plaque counts in carriers of the risk allele (N=6; 60.3±16.9) compared with non-carriers (N=9; 26.3±8.8; P=0.007). This study provides compelling evidence of a genetic and functional involvement of a common PLAU variant into the pathogenesis of AD. Further functional investigations are warranted to elucidate the specific role of PLAU, respectively, PLAU variants in the metabolism of Aβ proteins.
- 16 June 2006
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 15 (16) , 2446-2456
A functional polymorphism within plasminogen activator urokinase (PLAU) is associated with Alzheimer's disease
A number of susceptibility loci for Alzheimer's disease (AD) have been identified including a region on Chromosome 10q21–q22. Within this region the plasminogen activator urokinase gene (PLAU) was considered as a reasonable candidate from its functional implication in plasmin generation, a serine protease capable of degrading beta-Amyloid (Aβ) protein. We screened 56 single nucleotide polymorphisms (SNPs) around PLAU using 1751 individuals from four independent case–control samples (Munich, N=679; Bonn N=282; Brescia (Italy) N=219; Perth (Australia) N=557 and one discordant sib-pair sample (Munich N=622). In brain tissue samples of neuropathologically confirmed cases with AD (N=33) we analyzed plaque counts according to the risk allele. We identified that one functional exonic SNP (rs2227564) is associated with development of AD using the four independent case–control samples (Munich, P=0.02; Bonn, P=0.005; Brescia (Italy), P=0.001; Perth (Australia), P=0.03) and the discordant sib-pair sample (P=0.001). In brain tissue, from neuropathologically confirmed cases with AD, we identified significantly higher plaque counts in carriers of the risk allele (N=6; 60.3±16.9) compared with non-carriers (N=9; 26.3±8.8; P=0.007). This study provides compelling evidence of a genetic and functional involvement of a common PLAU variant into the pathogenesis of AD. Further functional investigations are warranted to elucidate the specific role of PLAU, respectively, PLAU variants in the metabolism of Aβ proteins.
- 27 July 2004
- Published by Wolters Kluwer Health in Neurology
- Vol. 63 (2) , 364-366
Prion protein codon 129 polymorphism and risk of Alzheimer disease
The authors investigated the PRNP Met129Val polymorphism in 1,393 subjects including 482 patients with Alzheimer disease (AD) and two independent control groups. In patients, PRNP Met homozygosity conferred increasing risk with decreasing age at onset (onset: 61 to 70 years, n = 151, p = 0.02, odds ratio [OR] = 1.72, 95% CI = 1.2 to 2.53; onset: ≤60 years, n = 138, p = 0.013, OR = 1.92, 95% CI = 1.31 to 2.87), whereas no association was obtained in patients with onset at older than 70 years. The results suggest involvement of the prion protein in the pathogenesis of early-onset AD.
- 27 July 2004
- Published by Wolters Kluwer Health in Neurology
- Vol. 63 (2) , 364-366
Prion protein codon 129 polymorphism and risk of Alzheimer disease
The authors investigated the PRNP Met129Val polymorphism in 1,393 subjects including 482 patients with Alzheimer disease (AD) and two independent control groups. In patients, PRNP Met homozygosity conferred increasing risk with decreasing age at onset (onset: 61 to 70 years, n = 151, p = 0.02, odds ratio [OR] = 1.72, 95% CI = 1.2 to 2.53; onset: ≤60 years, n = 138, p = 0.013, OR = 1.92, 95% CI = 1.31 to 2.87), whereas no association was obtained in patients with onset at older than 70 years. The results suggest involvement of the prion protein in the pathogenesis of early-onset AD.
- 18 March 2004
- Published by Elsevier in Neurobiology of Aging
- Vol. 25 (10) , 1305-1308
Association analysis of genes involved in cholesterol metabolism located within the linkage region on chromosome 10 and Alzheimer’s disease
- 18 March 2004
- Published by Elsevier in Neurobiology of Aging
- Vol. 25 (10) , 1305-1308
Association analysis of genes involved in cholesterol metabolism located within the linkage region on chromosome 10 and Alzheimer’s disease
- Open Access
- 27 March 2003
- Published by Springer Nature in Molecular Psychiatry
- Vol. 8 (3) , 343-347
Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt–Jakob disease from other dementias
Early clinical symptoms of sporadic Creutzfeldt–Jakob disease (CJD) may overlap with other neurodegenerative diseases like Alzheimer's disease (AD) and frontotemporal degeneration (FTD). On entering an era in which pharmaceutical treatment of CJD occurs, reliable diagnostic markers like immunodetection of 14–3–3 proteins in the cerebrospinal fluid (CSF) are required. However, false negative results in autopsy-proven, sporadic CJD cases, as well as false positive results in several other disorders including AD and FTD showing high CSF tau protein levels, limit the potential of this marker. Due to neuronal lysis the cytosolic fraction of total tau containing phosphorylated and non-phosphorylated isoforms is partially liberated into the CSF. Since hyperphosphorylation of tau may specifically occur in neurodegenerative diseases associated with neurofibrillary changes, we hypothesized that the phospho-tau (P-tau)/total tau ratio in CSF may be a useful marker to discriminate CJD from other neurodegenerative disorders. The P-tau/total tau ratio discriminated patients with CJD from all other neuro-degenerative disorders including patients with AD and FTD without any overlap. Although the results have to be confirmed in a larger sample, the preliminary data suggest that simultaneous measurement of total tau and P-tau in CSF may be useful to identify patients with CJD.
- 27 March 2003
- Published by Springer Nature in Molecular Psychiatry
- Vol. 8 (3) , 343-347
Open AccessPhospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt–Jakob disease from other dementias
Early clinical symptoms of sporadic Creutzfeldt–Jakob disease (CJD) may overlap with other neurodegenerative diseases like Alzheimer's disease (AD) and frontotemporal degeneration (FTD). On entering an era in which pharmaceutical treatment of CJD occurs, reliable diagnostic markers like immunodetection of 14–3–3 proteins in the cerebrospinal fluid (CSF) are required. However, false negative results in autopsy-proven, sporadic CJD cases, as well as false positive results in several other disorders including AD and FTD showing high CSF tau protein levels, limit the potential of this marker. Due to neuronal lysis the cytosolic fraction of total tau containing phosphorylated and non-phosphorylated isoforms is partially liberated into the CSF. Since hyperphosphorylation of tau may specifically occur in neurodegenerative diseases associated with neurofibrillary changes, we hypothesized that the phospho-tau (P-tau)/total tau ratio in CSF may be a useful marker to discriminate CJD from other neurodegenerative disorders. The P-tau/total tau ratio discriminated patients with CJD from all other neuro-degenerative disorders including patients with AD and FTD without any overlap. Although the results have to be confirmed in a larger sample, the preliminary data suggest that simultaneous measurement of total tau and P-tau in CSF may be useful to identify patients with CJD.
- Open Access
- 1 November 2002
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 59 (11) , 1729-1734
Cerebrospinal Fluid Tau and β-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive Impairment
Research from JAMA Neurology — Cerebrospinal Fluid Tau and β-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive Impairment
- 1 November 2002
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 59 (11) , 1729-1734
Open AccessCerebrospinal Fluid Tau and β-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive Impairment
Research from JAMA Neurology — Cerebrospinal Fluid Tau and β-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive Impairment
- 1 August 2002
- Published by Springer Nature in Molecular Psychiatry
- Vol. 7 (7) , 782-785
A polymorphism of the brain-derived neurotrophic factor (BDNF) is associated with Alzheimer's disease in patients lacking the Apolipoprotein E ε4 allele
Because of its implication in neuroprotection, formation of long lasting memories and a disturbed function in Alzheimer's disease (AD), brain-derived neurotrophic factor (BDNF) may represent an appropriate candidate gene conferring risk to AD. Recently, a single nucleotide polymorphism (C-270T) within the BDNF gene has been associated with late onset AD in a Japanese population giving an odds ratio (OR) of 3.8. Because of the importance of this finding we analysed the BDNF polymorphism in a German sample consisting of 210 patients with AD and 188 cognitively healthy controls. The T-allele frequency was higher in patients with AD (11.9%) compared to controls (6.9%) (P = 0.035; OR = 2.26; 95% CI: 1.04–4.48). The risk conferred by the T-allele was stronger in patients who lack the ApoE ε4 allele giving an OR of 2.61 (1.21–5.64) P = 0.015, particularly in patients with early onset of the disease; OR 3.13 (1.32–7.43); P= 0.01. Due to the small number of patients showing both, lack of the ApoE ε4 allele and the BDNF T allele (n = 18), the result needs to be confirmed in a larger sample. The results suggest that the BDNF C-270T polymorphism is a relevant risk factor for AD particularly in patients lacking the ApoE ε4 allele in this German sample.
- 1 August 2002
- Published by Springer Nature in Molecular Psychiatry
- Vol. 7 (7) , 782-785
A polymorphism of the brain-derived neurotrophic factor (BDNF) is associated with Alzheimer's disease in patients lacking the Apolipoprotein E ε4 allele
Because of its implication in neuroprotection, formation of long lasting memories and a disturbed function in Alzheimer's disease (AD), brain-derived neurotrophic factor (BDNF) may represent an appropriate candidate gene conferring risk to AD. Recently, a single nucleotide polymorphism (C-270T) within the BDNF gene has been associated with late onset AD in a Japanese population giving an odds ratio (OR) of 3.8. Because of the importance of this finding we analysed the BDNF polymorphism in a German sample consisting of 210 patients with AD and 188 cognitively healthy controls. The T-allele frequency was higher in patients with AD (11.9%) compared to controls (6.9%) (P = 0.035; OR = 2.26; 95% CI: 1.04–4.48). The risk conferred by the T-allele was stronger in patients who lack the ApoE ε4 allele giving an OR of 2.61 (1.21–5.64) P = 0.015, particularly in patients with early onset of the disease; OR 3.13 (1.32–7.43); P= 0.01. Due to the small number of patients showing both, lack of the ApoE ε4 allele and the BDNF T allele (n = 18), the result needs to be confirmed in a larger sample. The results suggest that the BDNF C-270T polymorphism is a relevant risk factor for AD particularly in patients lacking the ApoE ε4 allele in this German sample.